Edwards Lifesciences (EW) FCF Margin (2009 - 2026)

Edwards Lifesciences has reported FCF Margin for 18 years, with the latest figure at 33.6% in Q2 2026.

• On a quarterly basis, FCF Margin rose 1788.0% year-over-year to 33.6% in Q2 2026; TTM through Jun 2026 was 22.01%, a 1167.0% increase from a year earlier, with the FY2025 full-year figure at 22.0%, up 1667.0% from the prior year.
• FCF Margin was 33.6% for Q2 2026 at Edwards Lifesciences, up from 1.28% in the prior quarter.
• The five-year high for FCF Margin was 49.76% in Q4 2022, with the low at 12.79% in Q4 2024.
• Average FCF Margin over 5 years is 16.62%, with a median of 19.82% recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: FCF Margin slumped 4594 bps in 2023, then soared 3532 bps in 2025.
• Over 5 years, FCF Margin stood at 49.76% in 2022, then tumbled by 92 bps to 3.81% in 2023, then slumped by 435 bps to 12.79% in 2024, then soared by 276 bps to 22.52% in 2025, then soared by 49 bps to 33.6% in 2026.
• The last three FCF Margin figures came in at 33.6% (Q2 2026), 1.28% (Q1 2026), and 22.52% (Q4 2025), per Business Quant data.